Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company’s telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).
"The I-STAR?„? platform has been designed to discover broadly reactive, potent antibodies with high specificity for valuable targets," commented Dr. Steven Gillis, Interim Chief Executive Officer of Theraclone and Managing Director of ARCH Venture Partners. "This collaboration with Pfizer, and the recent published success of I-STAR?„? to identify unique antibodies against novel targets in HIV and influenza, increase confidence in Theraclone’s approach to search the human immune repertoire to isolate rare and powerful human antibodies that may be of use in the treatment of multiple diseases."
"Antibodies represent a very exciting class of biotherapeutics for Pfizer to combat infectious disease and are a proven approach to cancer treatment," commented Jose-Carlos Guti?©rrez-Ramos, Pfizer’s Senior Vice President of Worldwide BioTherapeutics Research & Development. "Theraclone’s platform technology represents an important advancement in fully-human therapeutic antibody discovery, which we believe has the potential to deliver a new generation of improved therapeutic antibodies more efficiently."
SOURCE Theraclone Sciences, Inc.,